Sensus Healthcare Croissance future

Future contrôle des critères 5/6

Sensus Healthcare devrait augmenter ses bénéfices et ses revenus de 26% et de 20.4% par an respectivement, tandis que le BPA devrait croître de croître de 25.2% par an.

Informations clés

26.0%

Taux de croissance des bénéfices

25.2%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices	17.0%
Taux de croissance des recettes	20.4%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	19 Nov 2024

Mises à jour récentes de la croissance future

Results: Sensus Healthcare, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Nov 19

Sensus Healthcare, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 11

Recent updates

Results: Sensus Healthcare, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Nov 19

Sensus Healthcare, Inc. (NASDAQ:SRTS) Doing What It Can To Lift Shares

Nov 12

At US$6.10, Is It Time To Put Sensus Healthcare, Inc. (NASDAQ:SRTS) On Your Watch List?

Oct 03

Returns At Sensus Healthcare (NASDAQ:SRTS) Are On The Way Up

May 12

Potential Upside For Sensus Healthcare, Inc. (NASDAQ:SRTS) Not Without Risk

Apr 16

Sensus Healthcare, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 11

There's Been No Shortage Of Growth Recently For Sensus Healthcare's (NASDAQ:SRTS) Returns On Capital

Oct 17

Sensus Healthcare (NASDAQ:SRTS) Might Have The Makings Of A Multi-Bagger

Jul 04

Lacklustre Performance Is Driving Sensus Healthcare, Inc.'s (NASDAQ:SRTS) 26% Price Drop

Mar 14

Analysts Just Made A Captivating Upgrade To Their Sensus Healthcare, Inc. (NASDAQ:SRTS) Forecasts

May 11

Investors Will Want Sensus Healthcare's (NASDAQ:SRTS) Growth In ROCE To Persist

Apr 29

Sensus Healthcare's (NASDAQ:SRTS) Earnings Are Of Questionable Quality

Apr 01

Are Investors Undervaluing Sensus Healthcare, Inc. (NASDAQ:SRTS) By 31%?

Dec 17

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:SRTS - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	66	15	9	9	3
12/31/2025	49	11	-8	-7	4
12/31/2024	39	7	-2	-2	4
9/30/2024	41	9	2	3	N/A
6/30/2024	36	7	-1	-1	N/A
3/31/2024	32	5	-5	-4	N/A
12/31/2023	24	0	-2	-2	N/A
9/30/2023	25	-1	-15	-15	N/A
6/30/2023	30	2	-12	-12	N/A
3/31/2023	38	6	-11	-10	N/A
12/31/2022	45	24	-2	-1	N/A
9/30/2022	44	27	7	7	N/A
6/30/2022	41	25	4	4	N/A
3/31/2022	34	21	4	4	N/A
12/31/2021	27	4	0	0	N/A
9/30/2021	19	0	1	1	N/A
6/30/2021	15	-2	-3	-3	N/A
3/31/2021	11	-4	-2	-2	N/A
12/31/2020	10	-7	-1	0	N/A
9/30/2020	13	-7	0	0	N/A
6/30/2020	17	-6	1	1	N/A
3/31/2020	24	-3	5	5	N/A
12/31/2019	27	-2	-3	-2	N/A
9/30/2019	27	-3	-5	-4	N/A
6/30/2019	27	-2	-5	-5	N/A
3/31/2019	26	-3	-13	-12	N/A
12/31/2018	26	-2	-9	-9	N/A
9/30/2018	25	-3	-7	-6	N/A
6/30/2018	23	-3	N/A	-5	N/A
3/31/2018	22	-3	N/A	-4	N/A
12/31/2017	21	-4	N/A	-3	N/A
9/30/2017	19	-3	N/A	-2	N/A
6/30/2017	18	-2	N/A	-3	N/A
3/31/2017	16	-2	N/A	-3	N/A
12/31/2016	15	0	N/A	-1	N/A
9/30/2016	14	0	N/A	-2	N/A
6/30/2016	13	0	N/A	-1	N/A
3/31/2016	11	0	N/A	-1	N/A
12/31/2015	10	-1	N/A	-1	N/A
9/30/2015	8	-2	N/A	-1	N/A
12/31/2014	6	-4	N/A	-2	N/A
12/31/2013	10	0	N/A	0	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de SRTS ( 26% par an) est supérieure au taux d'épargne ( 2.6% ).

Bénéfices vs marché: Les bénéfices de SRTS ( 26% par an) devraient croître plus rapidement que le marché US ( 15.4% par an).

Croissance élevée des bénéfices: Les bénéfices de SRTS devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de SRTS ( 20.4% par an) devrait croître plus rapidement que le marché US ( 9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de SRTS ( 20.4% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de SRTS devrait être élevé dans 3 ans

Sensus Healthcare Croissance future

Future contrôle des critères 5/6

Informations clés

Mises à jour récentes de la croissance future

Results: Sensus Healthcare, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Price target increased by 10% to US$11.00

Consensus EPS estimates increase by 25%

Sensus Healthcare, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Sensus Healthcare, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Price target decreased by 29% to US$10.90

Recent updates

Investor sentiment improves as stock rises 30%

Results: Sensus Healthcare, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target increased by 10% to US$11.00

Sensus Healthcare, Inc. (NASDAQ:SRTS) Doing What It Can To Lift Shares

At US$6.10, Is It Time To Put Sensus Healthcare, Inc. (NASDAQ:SRTS) On Your Watch List?

Investor sentiment deteriorates as stock falls 15%

Investor sentiment improves as stock rises 16%

Consensus EPS estimates increase by 25%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 15%

Independent Director recently sold US$123k worth of stock

Investor sentiment improves as stock rises 69%

Returns At Sensus Healthcare (NASDAQ:SRTS) Are On The Way Up

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Sensus Healthcare, Inc., Annual General Meeting, May 31, 2024

Potential Upside For Sensus Healthcare, Inc. (NASDAQ:SRTS) Not Without Risk

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Sensus Healthcare, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Sensus Healthcare Announces Directors Changes

Sensus Healthcare, Inc. to Report Q4, 2023 Results on Feb 08, 2024

New minor risk - Share price stability

Sensus Healthcare, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Sensus Healthcare, Inc. Appoints Michael Sardano as A Director, Effective February 1, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

There's Been No Shortage Of Growth Recently For Sensus Healthcare's (NASDAQ:SRTS) Returns On Capital

Sensus Healthcare to Showcase its Full Line of Cutting-Edge Superficial Radiotherapy Devices for the Treatment of Non-melanoma Skin Cancer at ASTRO 2023 in San Diego

New major risk - Earnings quality

Investor sentiment improves as stock rises 31%

Sensus Healthcare, Inc. (NasdaqCM:SRTS) announces an Equity Buyback for $3 million worth of its shares.

Second quarter 2023 earnings: EPS exceeds analyst expectations

New major risk - Share price stability

Sensus Healthcare (NASDAQ:SRTS) Might Have The Makings Of A Multi-Bagger

Independent Director recently bought US$60k worth of stock

Investor sentiment deteriorates as stock falls 37%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 29% to US$10.90

Full year 2022 earnings: EPS misses analyst expectations

Lacklustre Performance Is Driving Sensus Healthcare, Inc.'s (NASDAQ:SRTS) 26% Price Drop

Investor sentiment deteriorates as stock falls 17%

Do Sensus Healthcare's (NASDAQ:SRTS) Earnings Warrant Your Attention?

Now 20% undervalued

Consensus EPS estimates fall by 14%

Investor sentiment deteriorates as stock falls 16%

Full year 2022 earnings: EPS misses analyst expectations

Sensus Healthcare, Inc. Announces Senior Management Appointments and Promotions

Sensus Healthcare, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Sensus Healthcare, Inc. to Report Q4, 2022 Results on Feb 09, 2023

Investor sentiment deteriorated over the past week

Price target decreased to US$15.30

Insufficient new directors

Investor sentiment deteriorated over the past week

Price target decreased to US$15.30

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Sensus Healthcare, Inc. Introduces Silk(TM) Laser Hair Removal System

Now 23% undervalued

Sensus Healthcare (NASDAQ:SRTS) Could Become A Multi-Bagger

Now 21% undervalued

President & General Counsel notifies of intention to sell stock

Investor sentiment improved over the past week

Co-Founder recently sold US$521k worth of stock

Sensus Healthcare, Inc. Appoints Mohammad K. Khan to Medical Advisory Board

Now 22% undervalued

Co-Founder notifies of intention to sell stock

Independent Director recently sold US$710k worth of stock

Sensus Healthcare, Inc. Launches Upgrade to its SRT-100 Vision System with New Ultrasound Capabilities

Second quarter 2022 earnings released: EPS: US$0.21 (vs US$0.017 loss in 2Q 2021)

Sensus Healthcare Q2 GAAP EPS, revenue beats